

Jakub Rosik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1138143/publications.pdf>

Version: 2024-02-01

22
papers

1,070
citations

623188

14
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

1515
citing authors

#	ARTICLE	IF	CITATIONS
1	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resistance Updates, 2021, 59, 100794.	6.5	175
2	Betulin and its derivatives as novel compounds with different pharmacological effects. Biotechnology Advances, 2020, 38, 107409.	6.0	158
3	COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. Journal of Clinical Medicine, 2020, 9, 1917.	1.0	137
4	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates, 2020, 53, 100719.	6.5	110
5	Pleiotropic effects of statins: A focus on cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165968.	1.8	89
6	Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets. Cancers, 2021, 13, 909.	1.7	67
7	Aspirin and its pleiotropic application. European Journal of Pharmacology, 2020, 866, 172762.	1.7	64
8	COVID-19: Pain Management in Patients with SARS-CoV-2 Infection—Molecular Mechanisms, Challenges, and Perspectives. Brain Sciences, 2020, 10, 465.	1.1	52
9	The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitus. Annals of Human Genetics, 2020, 84, 114-124.	0.3	42
10	<p>New therapies for the treatment of heart failure: a summary of recent accomplishments</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 147-155.	0.9	29
11	Kidney damage from nonsteroidal anti-inflammatory drugs—Myth or truth? Review of selected literature. Pharmacology Research and Perspectives, 2021, 9, e00817.	1.1	27
12	<p>COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients</p>. Clinical Interventions in Aging, 2020, Volume 15, 1231-1240.	1.3	25
13	CTLA4 antagonists in phase I and phase II clinical trials, current status —and— future perspectives for cancer therapy. Expert Opinion on Investigational Drugs, 2019, 28, 149-159.	1.9	21
14	Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 617-626.	1.5	17
15	Potential targets of gene therapy in the treatment of heart failure. Expert Opinion on Therapeutic Targets, 2018, 22, 811-816.	1.5	13
16	The Role of BiP and the IRE1—XBP1 Axis in Rhabdomyosarcoma Pathology. Cancers, 2021, 13, 4927.	1.7	11
17	Reprogramming and transdifferentiation - two key processes for regenerative medicine. European Journal of Pharmacology, 2020, 882, 173202.	1.7	10
18	The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 85-99.	2.5	8

#	ARTICLE	IF	CITATIONS
19	The Genetic Variants in the Renin-Angiotensin System and the Risk of Heart Failure in Polish Patients. <i>Genes</i> , 2022, 13, 1257.	1.0	8
20	The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3081.	1.8	3
21	Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. <i>Viruses</i> , 2022, 14, 1092.	1.5	3
22	Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomes. <i>Expert Review of Hematology</i> , 2019, 12, 1089-1094.	1.0	1